This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of Journavx were posted to FDA’s online repository ...

Journavx will likely follow the trajectory of other newer drugs and be fairly costly On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets ...